Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
2024年2月28日 - 9:00PM
Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage
biopharmaceutical company discovering and developing clinically
differentiated small molecule therapeutics targeting fundamental
biological pathways of cancer, today announced that Zentalis
management will participate in several upcoming investor
conferences:
- TD Cowen 43rd Annual Health Care
Conference
- Location: Boston, MA
- Event: Gynecological Cancers Corporate Panel
Discussion
- Date and Time: March 5 at 10:30 a.m. ET
- Leerink Partners Global Biopharma
Conference
- Location: Miami, FL
- Event: Fireside discussion
- Date and Time: March 11 at 3:20 p.m. ET
- Jefferies Biotech on the Bay Summit
- Location: Miami, FL
- Event: Investor meetings only
- Date: March 12
Access to a live webcast of this event, as well as an archived
recording, will be available under the “Events & Presentations”
tab on the Investors & Media section of the Company’s
website.
About Zentalis Pharmaceuticals
Zentalis® Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company discovering and developing clinically
differentiated small molecule therapeutics targeting fundamental
biological pathways of cancers. The Company’s lead product
candidate, azenosertib (ZN-c3), is a potentially first-in-class and
best-in-class WEE1 inhibitor for advanced solid tumors and
hematologic malignancies. Azenosertib is being evaluated as a
monotherapy and in combination across multiple clinical trials and
has broad franchise potential. In clinical trials, azenosertib has
been well tolerated and has demonstrated anti-tumor activity as a
single agent across multiple tumor types and in combination with
several chemotherapy backbones. As part of its azenosertib clinical
development program, the Company is exploring enrichment strategies
targeting tumors of high genomic instability, such as Cyclin E1
positive tumors and homologous recombination deficient tumors. The
Company is also leveraging its extensive experience and
capabilities across cancer biology and medicinal chemistry to
advance its research on protein degraders. Zentalis has operations
in both New York and San Diego.
For more information, please visit www.zentalis.com. Follow
Zentalis on Twitter at @ZentalisP and on LinkedIn at
www.linkedin.com/company/zentalis-pharmaceuticals.
Contact:
Carlo Tanzi, Ph.D.Kendall Investor
Relationsctanzi@kendallir.com
Zentalis Pharmaceuticals (NASDAQ:ZNTL)
過去 株価チャート
から 8 2024 まで 9 2024
Zentalis Pharmaceuticals (NASDAQ:ZNTL)
過去 株価チャート
から 9 2023 まで 9 2024